Results 231 to 240 of about 6,212,855 (344)
Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median ...
Ki Hoon Kim +4 more
wiley +1 more source
A new kernel estimator of hazard ratio and its asymptotic mean squared error
, 2016 Taku Moriyama, Yoshihiko Maesono
openalex +2 more sources
A PANoptosis‐Based Signature for Survival and Immune Predication in Glioblastoma Multiforme
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective PANoptosis is a concept of total cell death characterized by pyroptosis, apoptosis, and necroptosis. We aimed to explore the clinical significance of PANoptosis‐related genes (PARGs) in glioblastoma multiforme (GBM). Methods Expression profiles of GBM were downloaded from the XENA database as a training dataset to construct a ...
Jun Yang +4 more
wiley +1 more source
Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Glioblastoma (GBM) is an aggressive brain tumor characterized by significant heterogeneity. This study investigates the role of glycosylation‐related genes in GBM subtyping, prognosis, and response to therapy. Methods We analyzed mRNA expression data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression ...
Tong Zhao +4 more
wiley +1 more source
Introducing a new estimator and test for the weighted all-cause hazard ratio. [PDF]
BMC Med Res Methodol, 2019 Ozga AK, Rauch G.
europepmc +1 more source
Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer. [PDF]
Transl Lung Cancer Res, 2020 Chen H +5 more
europepmc +1 more source
Hazard Ratio Bias in Cohort Studies
Epidemiology, 2013 Wen-Chung Lee, Jia-Chun Lin
openaire +2 more sources